- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04907357
rTMS for Stimulant Use Disorders (CTN-0108)
rTMS for Stimulant Use Disorders (CTN-0108)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be a randomized, double-blind, sham-controlled trial comparing rTMS vs. placebo delivered over an 8-week treatment period. After assessment and inclusion into the study, participants will be randomized to receive up to 30 sessions of either rTMS or placebo treatments. The target minimum number of rTMS/placebo treatments is 20 treatments over 8 weeks. The secondary objective is to gather preliminary data on the efficacy of rTMS for individuals with moderate to severe CUD or MUD. Follow-up visits occur at end of treatment and at 12- and 16-weeks following randomization.
Other study procedures:
Actigraphy: To assess daily sleep quality during weeks 1-8, the ActiGraph wristband device will record, sleep latency, sleep duration, and intervals of waking during the sleep period.
Electroencephalography (EEG): EEG will be obtained after randomization and again at week 4, to explore the potential for EEG to be used as a biomarker of treatment response.
Cognitive-Behavioral Educational Intervention: Participants in both conditions (rTMS and placebo) will be encouraged to participate in a mobile app-based educational intervention based on principles of Cognitive Behavioral Therapy (CBT) for Substance Use Disorder (SUD).
Daily Assessments: Brief, electronic remote surveys will be administered to participants daily until week 16 follow-up time point and will assess use of primary substance of abuse, craving, ability to resist use, overall mood, and self-rated sleep quality.
Urine Drug Screens (UDS): UDS will be collected at screening, randomization, every treatment session, and at follow-up visits.
Urine pregnancy tests: Pregnancy testing for all female participants will be performed at screening, randomization, and monthly during the treatment period.
Physical exam: A physical exam will be performed at screening.
Questionnaires: A battery of study assessments will be completed to further inform findings regarding feasibility and effects of rTMS on individuals with stimulant use disorders.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27101
- Wake Forest
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-65, inclusive
- Have a diagnosis of moderate or severe Cocaine or Methamphetamine Use Disorder (CUD/MUD) over the past 12 months (as determined by DSM-5 diagnostic criteria).
- Have used cocaine or methamphetamine on at least 10 of the last 30 days (based on Timeline Follow-Back).
- Be interested in decreasing cocaine and/or methamphetamine use.
- If female, willing to use appropriate birth control method during the treatment phase of the study.
- Be able to understand the study procedures and provide written informed consent to participate in the study.
- If prescribed benzodiazepines or anticonvulsants, must be on a stable dose for at least 4 weeks prior to consent.
Exclusion Criteria:
- A Diagnostic and Statistical Manual (DSM-5) diagnosis of moderate or severe SUD of any substance other than cocaine or methamphetamine based on DSM-5.
- History of a serious medical disorder that, in the opinion of the Medical Clinician, would make it unsafe to participate in the study or may prevent collection of study data.
- Is currently engaged in formal SUD treatment.
- Documented history of unprovoked seizure (lifetime) or any seizure in the past 6 months.
- Documented history of brain lesion(s) and/or tumor(s).
- Metal implants or non-removable metal objects above the waist.
- Currently pregnant.
- Lifetime history of prior clinical treatment with TMS.
- Current or lifetime bipolar disorder.
- Current psychotic disorder or psychotic depression.
- Serious risk of homicide or suicide.
- Are a prisoner or in police custody at the time of eligibility screening.
- Previously randomized as a participant in the study.
- Planned admission to a residential treatment facility or other formal SUD treatment program.
- Unwilling or unable to follow study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: rTMS
Participants will receive up to 30 rTMS sessions within the 8-week treatment period.
|
Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
Other Names:
|
Sham Comparator: Sham (Placebo)
Participants will receive up to 30 sham rTMS sessions within the 8-week treatment period.
|
Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants who receive at least 20 sessions of rTMS/sham over the treatment period.
Time Frame: From first treatment session (Week 1, first study visit) to end of treatment at 8 weeks
|
Treatment session attendance and completion will be tracked over the course of the study, and this record will constitute the primary feasibility outcome.
|
From first treatment session (Week 1, first study visit) to end of treatment at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of negative UDS from weekly UDS
Time Frame: From first treatment week (Week 1) to end of treatment at 8 weeks
|
A negative UDS for participants with cocaine as primary substance would be a UDS absent of cocaine; a negative UDS for participants with methamphetamine as primary substance would be a UDS absent of methamphetamine.
|
From first treatment week (Week 1) to end of treatment at 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kathleen T Brady, MD PHD, Medical University of South Carolina
- Principal Investigator: Madhukar Trivedi, MD, University of Texas South Western
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00107688
- UG1DA013727 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methamphetamine Use Disorder
-
University of NebraskaCompleted
-
Turning PointMonash University; Eastern Health; Deakin UniversityCompletedMethamphetamine Use DisorderAustralia
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)Terminated
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA)Not yet recruitingMethamphetamine Use DisorderUnited States
-
Turning PointMonash University; Eastern Health; National Centre for Clinical Research on Emerging...RecruitingMethamphetamine Use DisorderAustralia
-
Shanghai Mental Health CenterWuhan Mental Health Centre; Wuhan Judicial Bureau Hanyang Compulsory Isolated...Active, not recruitingMethamphetamine Use DisorderChina
-
Glenn-Milo SantosNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use DisorderUnited States
-
Craig RushNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Use DisorderUnited States
-
University of Texas Southwestern Medical CenterNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompletedMethamphetamine Use DisorderUnited States
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA); University of NebraskaRecruitingMethamphetamine Use DisorderUnited States
Clinical Trials on rTMS
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruiting
-
Chang Gung Memorial HospitalRecruiting
-
Changping LaboratoryBeijing HuiLongGuan HospitalRecruitingMajor Depressive Disorder | Severe Depression | Moderate DepressionChina
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre hospitalier de Ville-Evrard, FranceRecruitingTo Evaluate the Effectiveness of Open rTMSFrance
-
Stanford UniversityRecruitingMajor Depressive DisorderUnited States
-
Bayside HealthCompletedAutistic Disorder | Asperger's DisorderAustralia
-
Prof. Dominique de Quervain, MDRecruiting
-
Changping LaboratoryWuhan Mental Health CentreRecruitingMajor Depressive Disorder | Severe Depression | Moderate DepressionChina